157 related articles for article (PubMed ID: 8957091)
21. Modulation of gene expression by tumor-derived p53 mutants.
Scian MJ; Stagliano KE; Ellis MA; Hassan S; Bowman M; Miles MF; Deb SP; Deb S
Cancer Res; 2004 Oct; 64(20):7447-54. PubMed ID: 15492269
[TBL] [Abstract][Full Text] [Related]
22. Mutant p53 forms a complex with Sp1 on HIV-LTR DNA.
Chicas A; Molina P; Bargonetti J
Biochem Biophys Res Commun; 2000 Dec; 279(2):383-90. PubMed ID: 11118296
[TBL] [Abstract][Full Text] [Related]
23. CP-31398, a putative p53-stabilizing molecule tested in mammalian cells and in yeast for its effects on p53 transcriptional activity.
Tanner S; Barberis A
J Negat Results Biomed; 2004 Nov; 3():5. PubMed ID: 15548325
[TBL] [Abstract][Full Text] [Related]
24. Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments.
Caron de Fromentel C; Gruel N; Venot C; Debussche L; Conseiller E; Dureuil C; Teillaud JL; Tocque B; Bracco L
Oncogene; 1999 Jan; 18(2):551-7. PubMed ID: 9927212
[TBL] [Abstract][Full Text] [Related]
25. Specific binding of MAR/SAR DNA-elements by mutant p53.
Müller BF; Paulsen D; Deppert W
Oncogene; 1996 May; 12(9):1941-52. PubMed ID: 8649855
[TBL] [Abstract][Full Text] [Related]
26. Use of transcription reporters with novel p53 binding sites to target tumour cells expressing endogenous or virally transduced p53 mutants with altered sequence-specificity.
Gagnebin J; Kovar H; Kajava AV; Estreicher A; Jug G; Monnier P; Iggo R
Oncogene; 1998 Feb; 16(5):685-90. PubMed ID: 9482117
[TBL] [Abstract][Full Text] [Related]
27. Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay.
Maurici D; Monti P; Campomenosi P; North S; Frebourg T; Fronza G; Hainaut P
Oncogene; 2001 Jun; 20(27):3533-40. PubMed ID: 11429700
[TBL] [Abstract][Full Text] [Related]
28. [Relevance of p53 protein and its mutations for novel strategies in cancer therapy].
Müller P; Nenutil R; Vojtĕsek B
Cas Lek Cesk; 2004; 143(5):313-7. PubMed ID: 15305766
[TBL] [Abstract][Full Text] [Related]
29. Mutants of the tumour suppressor p53 L1 loop as second-site suppressors for restoring DNA binding to oncogenic p53 mutations: structural and biochemical insights.
Merabet A; Houlleberghs H; Maclagan K; Akanho E; Bui TT; Pagano B; Drake AF; Fraternali F; Nikolova PV
Biochem J; 2010 Mar; 427(2):225-36. PubMed ID: 20113312
[TBL] [Abstract][Full Text] [Related]
30. 'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain.
Lányi A; Deb D; Seymour RC; Ludes-Meyers JH; Subler MA; Deb S
Oncogene; 1998 Jun; 16(24):3169-76. PubMed ID: 9671396
[TBL] [Abstract][Full Text] [Related]
31. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes.
Willis A; Jung EJ; Wakefield T; Chen X
Oncogene; 2004 Mar; 23(13):2330-8. PubMed ID: 14743206
[TBL] [Abstract][Full Text] [Related]
32. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
Sigal A; Rotter V
Cancer Res; 2000 Dec; 60(24):6788-93. PubMed ID: 11156366
[TBL] [Abstract][Full Text] [Related]
33. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression.
Bossi G; Lapi E; Strano S; Rinaldo C; Blandino G; Sacchi A
Oncogene; 2006 Jan; 25(2):304-9. PubMed ID: 16170357
[TBL] [Abstract][Full Text] [Related]
34. Effects of p51/p63 missense mutations on transcriptional activities of p53 downstream gene promoters.
Kato S; Shimada A; Osada M; Ikawa S; Obinata M; Nakagawara A; Kanamaru R; Ishioka C
Cancer Res; 1999 Dec; 59(23):5908-11. PubMed ID: 10606233
[TBL] [Abstract][Full Text] [Related]
35. Target gene modulation in hepatocellular carcinomas by decreased DNA-binding of p53 mutations.
Kubicka S; Trautwein C; Niehof M; Manns M
Hepatology; 1997 Apr; 25(4):867-73. PubMed ID: 9096590
[TBL] [Abstract][Full Text] [Related]
36. Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy.
Wiman KG
Adv Cancer Res; 2007; 97():321-38. PubMed ID: 17419952
[TBL] [Abstract][Full Text] [Related]
37. Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast.
Grochova D; Vankova J; Damborsky J; Ravcukova B; Smarda J; Vojtesek B; Smardova J
Oncogene; 2008 Feb; 27(9):1243-52. PubMed ID: 17724467
[TBL] [Abstract][Full Text] [Related]
38. Differential effects of phosphorylation of rat p53 on transactivation of promoters derived from different p53 responsive genes.
Lohrum M; Scheidtmann KH
Oncogene; 1996 Dec; 13(12):2527-39. PubMed ID: 9000127
[TBL] [Abstract][Full Text] [Related]
39. COOH-terminal domain of p53 modulates p53-mediated transcriptional transactivation, cell growth, and apoptosis.
Zhou X; Wang XW; Xu L; Hagiwara K; Nagashima M; Wolkowicz R; Zurer I; Rotter V; Harris CC
Cancer Res; 1999 Feb; 59(4):843-8. PubMed ID: 10029073
[TBL] [Abstract][Full Text] [Related]
40. RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells.
Menendez JA; Lupu R
Int J Mol Med; 2005 Jan; 15(1):33-40. PubMed ID: 15583825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
